Skip to main content

Investors

Moberg Pharma’s share is listed on the main list at NASDAQ OMX Stockholm. The company’s long-term financial objectives (in 2-4 years) are to achieve an EBITDA margin of at least 25 percent under continued healthy growth.

Aktiekurs 17 Jun 2013 14:30
33.90 kr
1.19 %

Calendar/presentations

Next calendar event: 2017-08-08 Interim report for January - June 2017

Contact Investor
relations:

Peter Wolpert, CEO
Tel: +46 (0)8 522 307 08
Email: peter.wolpert@mobergpharma.se
 

IR Kontakt: Anna Ljung, CFO
Tel. +46 (0)8 522 307 01
Email: anna.ljung@mobergpharma.se

 

BD: Ingela Berglund, International Marketing Manager
Tel: +46 (0)8 522 307 12
Email: ingela.berglund@mobergpharma.se

Subscribe

Get our latest press releases and reports